Author

David T. Asuzu

National Institute of Neurological Disorders and StrokeORCID 0000-0001-7011-479XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Debjani MandaliD· 2 shared Dhruval Bhatt· 2 shared Dustin MullaneyiD· 2 shared Kenneth AldapeiD· 2 shared Nikhil Ramavenkat· 2 shared Prashant ChittiboinaiD· 2 shared Sheelu VargheseiD· 2 shared Zied AbdullaeviD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Debjani MandalORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 15, 2025

Variable Schwann cell merlin inactivation is targetable with TEAD1 inhibition in schwannomas.

Maxwell Thomas Laws, Dhruval Bhatt, Debjani Mandal…·Prashant Chittiboina

The paper identifies variable merlin inactivation in schwannomas and shows TEAD1 inhibition can reverse hippo signaling and suppress tumor growth.

1 citation

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 28, 2025

Phosphoproteomic dysregulation drives tumor proliferation in Cushing's disease

David T. Asuzu, Dhruval Bhatt, Dustin Mullaney…·Prashant Chittiboina

This study identifies phosphoproteomic dysregulation as a driver of tumor proliferation in Cushing's disease and demonstrates reversibility using an FDA-approved PP2A agonist.

DOI 10.1101/2025.09.28.679056

humanproteomics

𝕏 PostBluesky